Kanazawa University, Graduate School of Pharmaceutical Sciences, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan.
Advanced Science Research Center, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8640, Japan.
Contrast Media Mol Imaging. 2018 Jun 13;2018:4535476. doi: 10.1155/2018/4535476. eCollection 2018.
The vesicular acetylcholine transporter (VAChT), a presynaptic cholinergic neuron marker, is a potential internal molecular target for the development of an imaging agent for early diagnosis of neurodegenerative disorders with cognitive decline such as Alzheimer's disease (AD). Since vesamicol has been reported to bind to VAChT with high affinity, many vesamicol analogs have been studied as VAChT imaging agents for the diagnosis of cholinergic neurodeficit disorder. However, because many vesamicol analogs, as well as vesamicol, bound to sigma receptors ( and ) besides VAChT, almost all the vesamicol analogs have been shown to be unsuitable for clinical trials. In this report, the relationships between the chemical structure and the biological characteristics of these developed vesamicol analogs were investigated, especially the in vitro binding profile and the in vivo regional brain accumulation.
囊泡型乙酰胆碱转运体(VAChT)是一种突触前胆碱能神经元标志物,是开发用于早期诊断阿尔茨海默病(AD)等伴有认知能力下降的神经退行性疾病的成像剂的潜在内部分子靶点。由于已报道囊泡碱与 VAChT 具有高亲和力结合,因此许多囊泡碱类似物已被研究作为 VAChT 成像剂用于诊断胆碱能神经缺损障碍。然而,由于许多囊泡碱类似物以及囊泡碱除了与 VAChT 结合外,还与 sigma 受体(和)结合,因此几乎所有囊泡碱类似物都被证明不适合临床试验。在本报告中,研究了这些开发的囊泡碱类似物的化学结构与生物学特性之间的关系,特别是体外结合谱和体内区域性脑积累。